Picture EBD Group Asia Bio Partnering Forum 2023 Singapore 650x100px
Organisation › Details

Accession Therapeutics (GB)

Accession Therapeutics is developing novel immune-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity. Led by T cell receptor therapy pioneer Bent Jakobsen, PhD FMedSci, the company is leveraging its Trocept platform technology to develop a portfolio of next generation products to the IND/early clinical trial stage. By engineering viruses specifically directed to cancer cells and carrying a transgene coding for an antitumour or immune activator drug, Trocept products are expected to be highly specific, broad in action so as to kill all cancer cell variants present in a tumour, and potent in activating the full immune system arsenal. The effects of the antitumour drug and immune system activation caused by cancer cell lysis after viral infection combine synergistically to give this broad and potent response, as illustrated in the animation here: Dr Jakobsen is a founder of Adaptimmune and Immunocore which are both now listed on NASDAQ. Accession Therapeutics is backed by iGlobe Partners, Primavera Venture Partners, Birk Venture and other international biotech investors. It is based at ARC Oxford in the UK. *


Period Start 2021-09-20 established (approx)
Product Industry cancer immunotherapy (immuno-oncology, I-O)
Persons Person Jakobsen, Bent (Accession Therapeutics 202109– CEO before Adaptimmune + Immunocore + Avidex + IMM Oxford)
  Person 2 Robinson, Hans Ivar (Zelluna 201911 Board Chairman)
  Street Curch Lane
Lashford House, Dry Sandford
  City OX13 6JP Abingdon, Oxfordshire
    Address record changed: 2021-09-26
Basic data Employees n. a.
    * Document for �About Section�: Accession Therapeutics. (11/21/22). "Press Release: Accession Therapeutics Raises £16.6m to Advance Potent Immunotherapies towards Clinical Trials". Oxford.
Record changed: 2022-11-21


Picture EBD Group Whitepaper State of Innovation in Europe 650x200px

More documents for Accession Therapeutics (GB)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner Bionnale 2023 the Life Sciences Event 650x300px

» top